Theriva Biologics' VCN-01 Shows Survival Gains in Refractory Head and Neck Cancer — Theriva Biologics, Inc.

Event summary

VCN-01 Phase 1 trial in refractory HNSCC patients showed median overall survival of 10.3 to 17.3 months when combined with durvalumab.
Biomarker data supports VCN-01's stroma-degrading and immune-enhancing mechanisms.
Trial enrolled 20 patients across three arms with varying VCN-01 dosing schedules.
Results published in Clinical Cancer Research on June 11, 2026.

The big picture

Theriva Biologics' positive Phase 1 data for VCN-01 in refractory head and neck cancer comes as the oncology sector increasingly focuses on combination therapies to overcome immunotherapy resistance. The results suggest VCN-01's stroma-degrading mechanism could be a differentiating factor in a market dominated by checkpoint inhibitors. The next challenge will be demonstrating this efficacy at scale while navigating the competitive landscape of cancer immunotherapies.

What we're watching

Clinical Validation: Whether VCN-01's biomarker-supported mechanisms will translate to larger, more definitive trials.
Development Pathway: The pace at which Theriva advances VCN-01 into combination therapy trials with other immune modulators.
Commercial Potential: How these results position VCN-01 in the competitive landscape of immunotherapy-refractory HNSCC treatments.